$ cat ./records/gates-backed-cepi-launches-50-million-funding-call-for-rift-valle-2022.txt
Gates-Backed CEPI Launches $50 Million Funding Call for Rift Valley Fever Vaccine Phase Trials in Africa
[RECORD.TXT] · cat --full
CEPI — whose founding donors include the Gates Foundation — launched a $50 million funding call including $35 million from EU Horizon Europe for Rift Valley fever (RVF) vaccine Phase I and II clinical trials in endemic African settings. In September 2023, CEPI invested $28.5 million in a UC Davis-led trial of the DDVax RVF vaccine candidate in Tanzania. Rift Valley fever has no licensed human vaccine, carries up to 1 percent case fatality in humans, and destroys livestock — making it a One Health pandemic preparedness priority under CEPI's expanding pathogen portfolio.
Source: https://cepi.net/rift-valley-fever-vaccines-advance-new-50-million-cepi-and-eu-funding-call
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Becomes Founding Philanthropic Donor to World Bank Pandemic Fund at G20 Bali
Next →
Gates Foundation Commits Up to $125 Million to End Acute COVID-19 Phase and Strengthen Global Disease Monitoring
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.